Browse the evidence

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior glycemic control and weight loss compared to selective GLP-1 receptor agonists by improving beta-cell function, enhancing insulin sensitivity independent of weight loss, and modulating central appetite regulation.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective for lowering blood sugar and reducing body weight, often outperforming older GLP-1 drugs. It improves insulin sensitivity directly, not just through weight loss. Common side effects like nausea may be less severe due to the GIP component. It is prescribed for Type 2 Diabetes and Obesity.

High-dose semaglutide (2.4 mg once weekly) significantly reduces the risk of major adverse cardiovascular events in overweight or obese adults without diabetes who have pre-existing cardiovascular disease.

If you are overweight or obese and have existing heart disease (like a prior heart attack or stroke) but do not have diabetes, high-dose semaglutide (2.4 mg weekly) is a clinically proven intervention to significantly lower your risk of future cardiovascular events, including heart attack and stroke. This benefit is independent of diabetes status and is achieved through a once-weekly injection alongside standard heart medications.

Oral GLP-1 receptor agonists (orforglipron and oral semaglutide) produce clinically meaningful double-digit weight loss (11.2–13.6%) and cardiometabolic improvements in adults with obesity without diabetes, offering a viable alternative to injectable therapies.

Oral GLP-1 medications like orforglipron and oral semaglutide are now proven to help adults with obesity lose significant weight (11-13%) and improve heart health markers without needing injections. If you struggle with needles or prefer a pill, these are viable, effective options, though you should discuss specific dosing rules and potential side effects like nausea with your doctor.

Treatment with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, liraglutide 3.0 mg) or GLP-1/GIP co-agonists (tirzepatide) is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce weight and cardiovascular risk factors.

If you have overweight or obesity and are at moderate or high cardiovascular risk, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are recommended treatments that significantly reduce weight and cardiovascular risk factors, often more effectively than lifestyle changes alone.

Semaglutide, a GLP-1 receptor agonist, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity through glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation.

Semaglutide is a prescription medication for T2DM and obesity that works by mimicking a gut hormone to regulate blood sugar, reduce appetite, and slow digestion. It is available as a weekly injection or a daily pill. Clinical trials show significant weight loss (4-15%) and improved blood sugar control (HbA1c reduction of 1.0-1.8%). Common side effects include nausea, which often improves over time. It is recommended for patients with cardiovascular risk.

Semaglutide (2.4 mg weekly) induces significant weight loss (approx. 14.9%) in adults with obesity, superior to Liraglutide (3 mg daily) and placebo.

Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing nearly 15% weight loss in clinical trials. It works by targeting brain pathways that control appetite. While it requires weekly injections, its efficacy is superior to older daily GLP-1 medications.

Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 11% in diabetics) and superior weight reduction compared to Semaglutide 1mg in patients with type 2 diabetes.

Tirzepatide is a weekly injection for type 2 diabetes that also causes significant weight loss (up to 11% in trials). It works by mimicking two gut hormones (GIP and GLP-1). It has been shown to reduce weight more than Semaglutide 1mg in diabetic patients.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle modification, produces clinically significant and sustained mean body weight reductions of 14–16% in adults without type 2 diabetes and 9.6% in adults with type 2 diabetes.

If you have obesity or overweight with a related health issue (like high blood pressure or diabetes) and lifestyle changes alone haven't worked, talk to your doctor about semaglutide 2.4 mg. It is a once-weekly injection taken alongside a healthy diet and exercise. It is not a substitute for lifestyle changes but helps overcome the body's natural tendency to regain weight. Be aware of potential side effects and that the dose starts low and increases gradually to help your body adjust.

Semaglutide 2.4 mg improves cardiometabolic risk factors, including blood pressure, lipids, glycated hemoglobin, and C-reactive protein, extending benefits beyond weight loss alone.

Beyond weight loss, semaglutide 2.4 mg helps improve blood pressure, cholesterol, blood sugar control, and inflammation markers. This makes it particularly beneficial for patients with obesity who also have related health risks like hypertension or diabetes.

Long-term use of FDA-approved anti-obesity medications (AOMs) is necessary to maintain weight loss, as discontinuation leads to significant weight regain.

If you are using medication to lose weight, plan to use it long-term. Stopping the medication usually causes the weight to come back, along with the health risks. Work with your doctor to find a safe, sustainable long-term plan.

Semaglutide, administered via weekly subcutaneous injection, produces significant weight loss (mean 14.9% reduction) and improves insulin resistance, hypertension, and glycemia in adults with obesity (BMI ≥30 kg/m²).

Semaglutide is a weekly injection that helps you lose about 15% of your body weight and improves blood pressure and blood sugar. It works best when combined with a healthy diet and exercise. Common side effects like nausea are usually temporary. It is prescribed for people with a BMI of 30 or higher, or 27 or higher with health issues.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant weight loss (up to -9.5 kg with 15 mg dose) in patients with type 2 diabetes over 40 weeks.

Tirzepatide is a dual-acting injection that helps you lose up to 9.5 kg over 40 weeks. It works by mimicking hormones that regulate blood sugar and appetite. It is used for people with type 2 diabetes who need better control. Side effects like nausea are common but often temporary.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with specific benefits on stroke and weight loss.

If you have Type 2 Diabetes and are at high risk for heart attack or stroke, ask your doctor about GLP-1 receptor agonists (like Victoza, Ozempic, or Trulicity). These medications have been proven to significantly reduce the risk of major cardiovascular events and stroke. They also promote weight loss, which is an added benefit. They are available as injections (daily or weekly) and in some cases, oral tablets.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.

If you have Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection that lowers blood sugar and helps you lose significant weight, often outperforming other common diabetes medications and insulin. While it can cause temporary stomach issues like nausea, these are usually mild and manageable, and the long-term benefits for your heart, kidneys, and overall metabolic health are substantial.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) significantly reduce body weight and improve glycemic control in patients with Type 2 Diabetes and Obesity.

GLP-1 receptor agonists are highly effective for weight loss and blood sugar control in obesity and Type 2 Diabetes. Options include daily or weekly injections and oral tablets. Expect significant weight loss (15-24% depending on the drug) and improved metabolic health. Discuss specific drug choice (e.g., Semaglutide vs. Tirzepatide) with your doctor based on efficacy needs and administration preference.

Tirzepatid (5-15 mg weekly) produces superior HbA1c reduction (mean 1.87-2.59%) and body weight loss (up to 12.9 kg) compared to placebo, semaglutide, and insulin in patients with type 2 diabetes.

Tirzepatid is a once-weekly injection for Type 2 Diabetes that significantly lowers blood sugar (HbA1c) and promotes substantial weight loss, outperforming other common diabetes medications like semaglutide and insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects like nausea are manageable and tend to improve over time. It is approved for adults with T2D, often used alongside metformin or other drugs.

Tirzepatide produces superior weight loss and glycemic control compared to GLP-1 receptor agonists (e.g., semaglutide) by acting as a balanced dual GIP/GLP-1 receptor agonist, leveraging GIP-mediated effects on adipose tissue metabolism and insulin sensitivity.

Tirzepatide is a once-weekly injectable medication that targets both GLP-1 and GIP receptors. It has been shown to produce significant weight loss (up to 25% in some trials) and improve blood sugar control, often outperforming GLP-1-only drugs. It is prescribed for obesity and type 2 diabetes under medical supervision.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, sustained weight loss (5-20% body weight reduction) in adults with obesity or overweight with comorbidities, primarily by delaying gastric emptying and reducing central appetite signaling.

If you have obesity or overweight with related health issues, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available in Europe. They work by mimicking hormones that tell your brain you are full and slowing down digestion. While they require weekly injections and may cause temporary stomach issues, they can lead to significant, sustained weight loss (often 15% or more) when combined with diet and exercise changes. Older weight loss drugs are largely unavailable due to safety risks.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) produces significantly greater weight loss and glycemic control than semaglutide (a GLP-1 receptor agonist) in patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, tirzepatide (Mounjaro/Zepbound) is clinically shown to be more effective for weight loss and blood sugar control than semaglutide (Ozempic/Wegovy). It works by targeting two hormones (GLP-1 and GIP) rather than just one. Expect weekly injections and potential stomach upset initially, which usually improves as your dose increases. Consult your doctor to see if this stronger option is appropriate for your specific health profile.

Subcutaneous semaglutide 2.4 mg administered once weekly reduces the risk of death from cardiovascular causes by 20% in patients with overweight or obesity without diabetes, based on the SELECT trial.

If you have had a heart attack and are overweight or obese but do not have diabetes, ask your doctor about semaglutide 2.4 mg. It is taken once weekly and has been shown to significantly reduce the risk of dying from heart-related causes. Be aware of potential stomach issues and the high cost if not covered by insurance.

Continuous administration of GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produces significant weight loss (6-22%) and cardiovascular risk reduction, but discontinuation leads to rapid weight regain and loss of therapeutic benefits.

Obesity pharmacotherapy with GLP-1/GIP agonists is highly effective for weight loss and cardiovascular health, but it is not a 'cure' with a fixed end date. You must continue the medication long-term to maintain weight loss; stopping leads to rapid regain. Discuss with your doctor whether the benefits of continuous therapy outweigh the burden of daily/weekly injections and potential side effects.

GLP-1 and dual/triple agonist therapies (semaglutide, tirzepatide, retatrutide) produce double-digit mean weight loss (15-24%) in clinical trials, significantly exceeding older pharmacotherapies.

If you have obesity, newer GLP-1 or dual/triple agonist medications can help you lose 15-20% of your body weight, which is significantly more than older drugs. These are taken as weekly injections (or soon, oral pills). You must discuss insurance coverage and potential side effects like nausea with your doctor, as cost and access are major hurdles.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce substantial weight loss (10-25%) and improve glycemic control through appetite suppression and enhanced satiety.

GLP-1 and GIP/GLP-1 agonists are highly effective for weight loss, achieving 10-25% reduction. They work by suppressing appetite and increasing satiety. Treatment requires a gradual dose increase to manage common gastrointestinal side effects like nausea. These drugs are indicated for adults with obesity or overweight with comorbidities, and should be used alongside lifestyle changes.

At maximum approved doses, tirzepatide (15 mg) produces significantly greater weight loss and glycemic improvement than semaglutide (2.4 mg).

If you are treating obesity with GLP-1/GIP agonists at their maximum FDA-approved doses, Tirzepatide (15 mg) will likely produce more weight loss and better blood sugar control than Semaglutide (2.4 mg). However, cost and availability may make Semaglutide a more practical first choice for some patients.